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Abstract 
There are differences in how European and American 
companies are managed.  American companies have 
one primary goal: to make money.  European 
companies often have multiple objectives.  We present 
a hypothesis that American companies have better 
short-term profit performance when compared to their 
European counterparts.   
 A comparison is performed with financial ratios 
using publicly available information.  While U.S. 
companies tend to be fairly similar, the European 
businesses are not so homogeneous.  We find that there 
are differences between the U.S. and European 
companies, and the hypothesis is supported by the 
analysis. 
 
Introduction 
No matter what their stated objectives, American 
companies are in business to make money for their 
shareholders.  They may do this in different ways, and 
have a variety of secondary objectives.  Company 
missions are often guiding principles, and may contain 
lofty ideals, but secondary objectives tend to support 
the primary objective of making a profit. 
 European companies often have multiple 
objectives.  The goal of making money is nearly 
always one of the stated objectives, but often there are 
other, sometimes more important goals.  One of the 
primary objectives, sometimes the primary objective, is 
to provide employment for people.  This is one way 
that the corporation supports the country where it is 
headquartered.  In Germany, unions represent much of 
the labor force.  These unions typically have a voice in 
the highest levels of the corporation. 
 Cultural differences have manifested themselves in 
different ways when it comes to managing the 
corporation.  In the U.S., the Board of Directors 
ultimately manages the corporation (presumably 
representing the best interest of the shareholders).  
These boards are made up of company executives and 
outside directors.  In recent years, there has been a 
move in the U.S. to increase the number of outside 
directors, and to decrease the relative influence of 
corporate executives.  While the company management 
handles the day-to-day decisions, strategy and long 
term planning tend to be controlled by the Board of 
Directors. 
 European companies are in many ways similar, but 
the control mechanisms can be different.  In the U.K., 
companies are managed much like those in the U.S., 
with a management board at the top of the corporate 
hierarchy.  In Germany, a two-tiered model is used.  
The Management board, made up of company 
executives, manages the day-to-day operation of the 
company.  The Supervisory board oversees and 
approves the actions of the Management Board.  This 
Supervisory Board is typically made up of 50% labor 
representation.  This ensures that the interests of the 
workers are protected. (Cunningham, 1998)  Aventis, 
which is a French-German merger, follows the German 
system. (Aventis, 2002) In Switzerland, there are no 
rules regarding corporate governance, and many 
different models are followed.  Our two Swiss 
companies of interest both have Management Boards, 
but they differ from the U.S. model in that nearly all of 
the people are corporate executives, with little outside 
influence.  (Novartis, 2002; Roche, 2002) 
 We have formed a hypothesis that American 
companies will have better short-term profit 
performance when compared to their European 
counterparts.  Because of the American focus on the 
present, coupled with the current single-minded focus 
on near-term profit, we felt that this should be found in 
comparing similar companies.  Also, we speculate that 
the near-term investment opportunities (stock 
ownership) would be better in the American 
companies.  The pharmaceutical business was chosen 
for this study. 
 
Method 
Today’s pharmaceutical business is represented by a 
number of very large multi-national corporations.  No 
one company holds a commanding market share.  The 
top ten worldwide companies, based on their level of 
pharmaceutical sales (expressed in dollar terms), 
contain a mixture of American and European 
companies.  The largest Japanese firm is in about 14th 
place.  For our comparison, we chose the top five 
American companies and the top five European 
companies based on dollar sales of pharmaceuticals as 
of the beginning of 2000. (Price Waterhouse Coopers, 
2002) Neither American nor European companies 
dominate the list.  The comparison companies are 
shown in Exhibit 1. 
 
 Companies that were not included in the study, but 
that would make up the next five in size, include 
Wyeth (formerly known as American Home Products), 
Eli Lilly, Schering-Plough, Takeda, and Abbott.  
Takeda is a Japanese company, whereas the remainder 
are American firms. 
 
Exhibit 1.  American and European comparison 
companies. 
  
 U.S. 
 Bristol-Myers Squibb 
 Johnson & Johnson 
 Merck 
 Pfizer 
 Pharmacia 
 
Europe 
AstraZeneca (United Kingdom) 
Aventis (France) 
Glaxo SmithKline (United Kingdom) 
Novartis (Switzerland) 
Roche (Switzerland) 
 
 
 The comparison was based on an analysis of 
financial ratios during the period of 1998 through 2002.  
Primary data were obtained from independent financial 
analysts, primarily the Market Guide / ProVestor report 
from Multex.com, Inc. and from Standard & Poor’s 
stock reports. (Multex, 2003; Standard & Poor’s, 2003)  
Additional information was obtained from company 
annual reports and Internet websites during the period.  
Public financial data were recorded and used to 
calculate financial ratios. 
 Two items complicated the analysis.  First, all U.S. 
based companies follow U.S. accounting practices, 
known as GAAP.  All of our EU companies are listed 
on the New York Stock Exchange, and therefore are 
required to publish GAAP information in their 
financial reports.  European companies follow their 
own country’s accounting practices; the corporations 
are controlled and decisions are made based on 
accounting practices other than GAAP.  What may 
appear as healthy profit in the United Kingdom, for 
example, may not look the same when expressed in 
terms according to U.S. GAAP.  The difference in 
accounting procedures proved to be a problem when 
making comparisons.  Because of this issue, financial 
results were taken primarily from independent research 
rather than from the companies’ annual reports. 
 The second complication resulted from recent 
merger activity.  There have been numerous mergers 
and acquisitions in the pharmaceutical industry over 
the past few years.  This distorts the financial 
information not only because of the merger of financial 
results, but also due to differences in accounting 
practices.  What is considered capital in one country 
may be considered expense in another.  This can have a 
profound impact on stated earnings in a given year.  
Several of our comparison companies were paying one-
time unique fees related to recent merger activities.  
Some of the significant merger and acquisition 
activities of these companies is listed in Exhibit 2.  
Notably, only three of our comparison companies were 
not involved in major merger activities during this time 
(Merck, Novartis, and Roche).   
 
Exhibit 2.  Mergers and Acquisitions 
 
1999 Aventis formed by the merger of Rhone-
Poulenc (France) and Hoechst (Germany) 
1999 AstraZeneca formed by the merger of Astra 
(Sweden) and Zeneca (U.K.) 
2000 Glaxo Smithkline formed by the merger of 
Glaxo Welcome (U.K.) and Smithkline 
Beecham (U.K.) 
2000 Pfizer (U.S.) acquired Warner Lambert (U.S.) 
2000 Pharmacia & Upjohn (previously Swedish, but 
relocated to the U.S.) acquired Monsanto 
(U.S.) and was renamed Pharmacia. 
2000  Johnson & Johnson (U.S.) acquired Centocor 
(U.S.) 
2001 Johnson & Johnson acquired ALZA (U.S.) 
2001 Bristol-Myers Squibb (U.S.) acquired DuPont 
Pharmaceuticals (U.S.) and divested Clairol 
beauty products 
2002 Pfizer announces the acquisition of Pharmacia 
(U.S.); became effective in April 2003. 
 
  (Aventis, 2002; AstraZeneca, 2002; Glaxo 
SmithKline, 2002; Pfizer, 2002; Pharmacia, 
2002; Johnson & Johnson, 2002; Bristol-
Myers Squibb, 2002) 
 
 
 Pharmacia is an American company, but this is a 
fairly recent event.  Pharmacia began as a Swedish 
Company, and later moved its headquarters to London.  
In the late 1990’s, the company moved its headquarters 
from London to New Jersey to be in the center of the 
worldwide pharmaceutical business.  During the data 
analysis phase, we decided to identify Pharmacia 
separately because its results in the late 90’s tended to 
be more like a European company than an American 
one. 
 
Results 
Various financial ratios reflect some of the differences 
that were expected, verifying our hypothesis.  Of the 
companies studied, the U.S companies achieved higher 
profit margin (15.8%) on average than their European 
counterparts (5.4%). The profit margins for our 
comparison companies during the study period are 
shown in Exhibit 3.  Some of the differences are due to 
accounting practices in how expenses are accounted. 
However, we feel that this also demonstrates 
differences in how the companies view short-term 
profit. The differences in the ratios also indicate that 
European companies prefer to use more debt to fund 
their projects. Hence, the increased interest expense 
reduces profit.   
 
Exhibit 3, Profit Margin. 
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Exhibit 4 shows the relation of market/book value with 
the profit margin. In this and other scatter plots, each 
data point represents one company’s results for one 
year; each company will have five data points.  It is 
evident here that the U.S companies show strong 
market/book value and higher profit margin than the 
European companies. This demonstrates the high 
regard that investors place in these American 
companies. 
 
Exhibit 4.  Market / Book value and Profit Margin 
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European companies appear to be willing to take 
on more debt than the American companies. An 
example is the debt-to-equity ratio, where the European 
companies averaged higher than the American firms. 
Another difference is how this debt is funded. 
American companies use a variety of debt instruments, 
including commercial paper for short term debt and 
corporate bonds for long-term debt. (Brigham, 2002) 
European companies tend to have close partnerships 
with their local banks and typically fund debt by taking 
out bank loans. This European practice tends to keep 
tighter control over the debt; there are few stakeholders 
involved. Americans fund their companies primarily 
with equity, while many (but not all) European 
companies fund their companies primarily with loans 
from their bankers. (Portanger, 2003)  The debt-to-
equity ratios are shown in Exhibit 5.  It can be seen that 
Bristol-Myers Squibb has been significantly increasing 
their use of debt in recent years.  The company has had 
financial and management problems, and has not been 
able to raise funds through the sale of equity.  They 
have instead increased their use of debt instruments.  
Pharmacia, on the other hand, has been adopting 
American business practices, and has been reducing 
their debt load.  
 
Exhibit 5.  Debt to equity ratios. 
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Exhibit 6 shows the relation of the debt-to-asset 
ratio with the debt-to-equity ratio. We can see here that  
 
Exhibit 6.  Debt/Equity and Debt/Assets 
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most of the European companies have higher ratios 
than the American companies. 
As most American companies have a lower debt 
ratio, they show a better return on assets and therefore 
demonstrate a good use of debt.  Exhibit 7 shows the 
relation of Return on Equity with Return on Assets.  It 
is apparent that the U.S. companies have better return 
on assets and return on equity compared to the 
European companies.  Some of this relates to asset 
utilization.  The European pharmaceutical production  
model involves a 5-day 2-shift work week, with the 3rd 
shift devoted primarily as a clean-up shift.  The typical 
European pharmaceutical company will produce 
product about 80 hours per week or less.  Some 
European companies have work weeks that are 
significantly shorter than 40 hours.  The American 
equivalent is to produce 24 hours a day, using the 
production assets 120 or more hours per week.  The 
higher return on assets numbers for the American 
companies reinforces this operational difference. 
 
Exhibit 7.  Return on Assets and Return on Equity 
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There is also a clear relationship between return-
on-assets and market/book value, as expected. 
Companies that have a higher ROA will be rewarded  
 
Exhibit 8.  Market/Book ratio and Return on Assets 
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with a high market/book value. The U.S. companies 
again emerge superior to the European companies as 
shown in Exhibit 8. 
Exhibit 9 illustrates the relationship between fixed 
asset turnover and return on equity.  The U.S. 
companies have a better fixed asset turnover ratio 
compared to their European counterparts.  The higher 
return on equity reflects this.  The graph reveals that 
the American companies are obtaining greater 
productivity from their existing fixed assets, as 
discussed earlier. 
 
Exhibit 9.  Fixed Asset Turnover and Return on Equity 
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Free cash flow analysis is an ideal benchmark for 
corporate valuation.  The technique eliminates the 
effect of national accounting practices such as 
depreciation or accounting of deferred taxes, allowing 
easy comparison across countries and industries.  
Exhibit 10 shows the free cash flows (FCF) for all of 
the companies.  Except for Bristol-Myers Squibb, all of 
the American companies have a high free cash flow 
ratio.   
 
Exhibit 10.  Free Cash Flow 
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The fact that Bristol-Myers Squibb is making 
heavier use of debt is making it difficult to maintain its 
free cash flow.  A negative current FCF is not 
necessarily bad in the short term, provided it is due to 
high growth.  The problem is that sales of Bristol have 
been declining over the past five years and this can be a 
very serious problem for the company.  On the other 
hand, most European companies except Novartis have 
modest free cash available for their operations. 
 
Conclusions 
Among the companies in our study, the American 
companies carry less debt than the average European 
company.  Market/book values tend to be higher 
among the American companies; this demonstrates the 
high regard that investors place in these companies.  
Most American companies have higher return on 
assets.   In addition, these companies have a higher free 
cash flow.  This is partially due to carrying less debt, 
and partially due to having greater utilization of their 
real assets.   
There is sufficient evidence to support our 
hypothesis: the American companies are delivering 
better short-term performance than their European 
counterparts. As a result, the U.S. companies are 
viewed as better short-term investments by the market. 
A key feature is that the American firms are focused on 
providing stockholders satisfaction.  
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